Glioblastoma: Defining Tumor Niches.
暂无分享,去创建一个
[1] M. Prados,et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. , 2016, Neuro-oncology.
[2] G. Semenza,et al. The hypoxic tumor microenvironment: A driving force for breast cancer progression. , 2016, Biochimica et biophysica acta.
[3] G. Bergers,et al. Tumor angiogenesis, from foe to friend , 2015, Science.
[4] P. Vajkoczy,et al. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells , 2015, International journal of cancer.
[5] R. Bourgon,et al. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] K. Aldape,et al. Macitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in Mice , 2015, Clinical Cancer Research.
[7] J. Rich,et al. Cancer stem cells in glioblastoma , 2015, Genes & development.
[8] Parag Mallick,et al. Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion , 2015, Cell.
[9] Gabriele Bergers,et al. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. , 2015, Cell reports.
[10] Brian Ruffell,et al. Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.
[11] Jennie W. Taylor,et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] G. Bergers,et al. Intertwined regulation of angiogenesis and immunity by myeloid cells. , 2015, Trends in immunology.
[13] Zhihong Chen,et al. Loss of CX3CR1 increases accumulation of inflammatory monocytes and promotes gliomagenesis , 2015, Oncotarget.
[14] D. Born,et al. Periostin is a novel therapeutic target that predicts and regulates glioma malignancy. , 2015, Neuro-oncology.
[15] Michael D. Brooks,et al. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. , 2015, Current pharmaceutical design.
[16] T. Langmann,et al. Glioma-Associated Microglia/Macrophages Display an Expression Profile Different from M1 and M2 Polarization and Highly Express Gpnmb and Spp1 , 2015, PloS one.
[17] H. Dvorak. Tumors: Wounds That Do Not Heal—Redux , 2015, Cancer Immunology Research.
[18] William A. Flavahan,et al. Periostin Secreted by Glioblastoma Stem Cells Recruits M2 Tumor-associated Macrophages and Promotes Malignant Growth , 2014, Nature Cell Biology.
[19] Helmut Kettenmann,et al. The role of microglia and macrophages in glioma maintenance and progression , 2015, Nature Neuroscience.
[20] H. Kettenmann,et al. Glioma‐associated microglial MMP9 expression is upregulated by TLR2 signaling and sensitive to minocycline , 2014, International journal of cancer.
[21] H. Weiner,et al. Differential roles of microglia and monocytes in the inflamed central nervous system , 2014, The Journal of experimental medicine.
[22] Harald Sontheimer,et al. A neurocentric perspective on glioma invasion , 2014, Nature Reviews Neuroscience.
[23] Harald Sontheimer,et al. Disruption of astrocyte-vascular coupling and the blood-brain barrier by invading glioma cells , 2014, Nature Communications.
[24] Shawn M. Gillespie,et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma , 2014, Science.
[25] Brian L. West,et al. Colony-Stimulating Factor 1 Receptor Signaling Is Necessary for Microglia Viability, Unmasking a Microglia Progenitor Cell in the Adult Brain , 2014, Neuron.
[26] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[27] S. Weiss,et al. Therapeutic activation of macrophages and microglia to suppress brain tumor-initiating cells , 2013, Nature Neuroscience.
[28] M. Mazzone,et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. , 2013, Cancer cell.
[29] G. Fuller,et al. Neutrophils Promote the Malignant Glioma Phenotype through S100A4 , 2013, Clinical Cancer Research.
[30] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[31] Christina S. Leslie,et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression , 2013, Nature Medicine.
[32] H. Kettenmann,et al. Distinct roles of CSF family cytokines in macrophage infiltration and activation in glioma progression and injury response , 2013, The Journal of pathology.
[33] David E. Anderson,et al. Tumor-Associated Macrophages in Glioma: Friend or Foe? , 2013, Journal of oncology.
[34] N. Abbott. Blood–brain barrier structure and function and the challenges for CNS drug delivery , 2013, Journal of Inherited Metabolic Disease.
[35] P. LaViolette,et al. Vascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma. , 2013, Neuro-oncology.
[36] R. McLendon,et al. Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.
[37] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[38] T. Acker,et al. The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. , 2013, Biochimica et biophysica acta.
[39] A. Mildner,et al. Fate mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis. , 2013, Immunity.
[40] F. Kirchhoff,et al. Microglia: New Roles for the Synaptic Stripper , 2013, Neuron.
[41] G. Bergers,et al. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. , 2013, CNS oncology.
[42] J. Heymach,et al. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. , 2012, Neuro-oncology.
[43] R. Weinberg,et al. Cancer stem cells and epithelial-mesenchymal transition: concepts and molecular links. , 2012, Seminars in cancer biology.
[44] M. Berger,et al. Increased Microglia/Macrophage Gene Expression in a Subset of Adult and Pediatric Astrocytomas , 2012, PloS one.
[45] H. Okada,et al. Myeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-Development , 2012, Immunological investigations.
[46] D. Cheresh,et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.
[47] Peng Zhang,et al. Tumor-Associated Microglia/Macrophages Enhance the Invasion of Glioma Stem-like Cells via TGF-β1 Signaling Pathway , 2012, The Journal of Immunology.
[48] J. Segall,et al. Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling , 2012, Molecular medicine.
[49] A. Sloan,et al. Hypoxia-induced mixed-lineage leukemia 1 regulates glioma stem cell tumorigenic potential , 2011, Cell Death and Differentiation.
[50] Debyani Chakravarty,et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.
[51] R. Ransohoff,et al. The Fractalkine Receptor but Not CCR2 Is Present on Microglia from Embryonic Development throughout Adulthood , 2012, The Journal of Immunology.
[52] K. Ligon,et al. Neoplastic cells are a rare component in human glioblastoma microvasculature , 2012, Oncotarget.
[53] D. Brat. Glioblastoma: biology, genetics, and behavior. , 2012, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[54] Rebecca A Betensky,et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.
[55] Manfred Westphal,et al. The neurobiology of gliomas: from cell biology to the development of therapeutic approaches , 2011, Nature Reviews Neuroscience.
[56] H. Fine,et al. Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. , 2011, Journal of the National Cancer Institute.
[57] Helmut Kettenmann,et al. The brain tumor microenvironment , 2011, Glia.
[58] H. Ng,et al. LABORATORY INVESTIGATION- HUMAN/ANIMAL TISSUE Clinical significance of vasculogenic mimicry in human gliomas , 2022 .
[59] Fei Li,et al. Glioma-initiating cells: A predominant role in microglia/macrophages tropism to glioma , 2011, Journal of Neuroimmunology.
[60] E. Bar,et al. Glioblastoma, Cancer Stem Cells and Hypoxia , 2011, Brain pathology.
[61] S. Pastorino,et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.
[62] L. Ricci-Vitiani,et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.
[63] Mauro Biffoni,et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.
[64] Rong Wang,et al. Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.
[65] B. Barres,et al. Pericytes are required for blood–brain barrier integrity during embryogenesis , 2010, Nature.
[66] F. Ginhoux,et al. Fate Mapping Analysis Reveals That Adult Microglia Derive from Primitive Macrophages , 2010, Science.
[67] A. Heimberger,et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. , 2010, Neuro-oncology.
[68] R. Ransohoff,et al. Selective Chemokine Receptor Usage by Central Nervous System Myeloid Cells in CCR2-Red Fluorescent Protein Knock-In Mice , 2010, PloS one.
[69] C. Eberhart,et al. Hypoxia increases the expression of stem-cell markers and promotes clonogenicity in glioblastoma neurospheres. , 2010, The American journal of pathology.
[70] K. P. Lehre,et al. The perivascular astroglial sheath provides a complete covering of the brain microvessels: An electron microscopic 3D reconstruction , 2010, Glia.
[71] Tracy T Batchelor,et al. Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. , 2010, Neuro-oncology.
[72] P. Gutin,et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma , 2009, Neurology.
[73] Jeffrey W. Pollard,et al. Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.
[74] M. Wolter,et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. , 2010, Brain : a journal of neurology.
[75] M. Frosch,et al. Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] G. Semenza. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.
[77] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[78] M. Aghi,et al. Mechanisms of evasion to antiangiogenic therapy in glioblastoma. , 2010, Clinical neurosurgery.
[79] J. Engh,et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α , 2009, Oncogene.
[80] P. Keegan,et al. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. , 2009, The oncologist.
[81] Hua Yu,et al. Stat3 inhibition activates tumor macrophages and abrogates glioma growth in mice , 2009, Glia.
[82] Hui Wang,et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. , 2009, Cancer cell.
[83] M. Stratton,et al. The cancer genome , 2009, Nature.
[84] Masahiro Inoue,et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.
[85] G. Bergers. Bone Marrow-Derived Cells in GBM Neovascularization , 2009 .
[86] N. Ferrara,et al. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[87] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[88] Gabriele Bergers,et al. Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.
[89] S. Vandenberg,et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. , 2008, Neuro-oncology.
[90] C. Cordon-Cardo,et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. , 2008, Cancer research.
[91] Harald Sontheimer,et al. A role for glutamate in growth and invasion of primary brain tumors , 2008, Journal of neurochemistry.
[92] S. Vandenberg,et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.
[93] F. Rossi,et al. Local self-renewal can sustain CNS microglia maintenance and function throughout adult life , 2007, Nature Neuroscience.
[94] M. Westphal,et al. Hypoxia can induce c‐Met expression in glioma cells and enhance SF/HGF‐induced cell migration , 2007, International journal of cancer.
[95] Ivan Radovanovic,et al. HEDGEHOG-GLI1 Signaling Regulates Human Glioma Growth, Cancer Stem Cell Self-Renewal, and Tumorigenicity , 2007, Current Biology.
[96] I. Bayazitov,et al. A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.
[97] H. Yee,et al. Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion , 2006, Laboratory Investigation.
[98] J. Lennerz,et al. Neuropathology for the neuroradiologist: palisades and pseudopalisades. , 2006, AJNR. American journal of neuroradiology.
[99] Qiulian Wu,et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. , 2006, Cancer research.
[100] C. Gondi,et al. Proteases and Glioma Angiogenesis , 2005, Brain pathology.
[101] Steven Song,et al. The role of pericytes in blood-vessel formation and maintenance. , 2005, Neuro-oncology.
[102] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[103] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[104] Daniel J Brat,et al. Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma , 2004, Laboratory Investigation.
[105] Daniel J Brat,et al. Pseudopalisades in Glioblastoma Are Hypoxic, Express Extracellular Matrix Proteases, and Are Formed by an Actively Migrating Cell Population , 2004, Cancer Research.
[106] Steffen Jung,et al. Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.
[107] A. Becker,et al. Analysis of the TP53 gene in laser-microdissected glioblastoma vasculature , 2003, Acta Neuropathologica.
[108] P. Allavena,et al. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. , 2002, Trends in immunology.
[109] Andrew V. Nguyen,et al. Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.
[110] Stanley J. Wiegand,et al. Vascular-specific growth factors and blood vessel formation , 2000, Nature.
[111] M. Westphal,et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.
[112] P. Nowell. Mechanisms of tumor progression. , 1986, Cancer research.